Merck's Q2 2010 earnings call highlights continued success in executing their post-merger strategy, despite patent expirations and economic headwinds.  Management expressed confidence in achieving long-term financial targets, focusing on cost synergies, product diversification, and robust pipeline growth.  However, the call also acknowledged challenges in some European markets due to austerity measures, which are expected to impact revenues in the second half.
[1]
